7 completed, 6 recruiting, 4 unknown, 2 withdrawn. 20 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 7, Recruiting 6, Unknown 4, Withdrawn 2, Terminated 1 |
| Phase 2 | 8 | Completed 3, Unknown 3, Recruiting 2 |
Follow Stomach Cancer: new trials by email Literature Review of Stomach Cancer trials Research Report on Stomach Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of IM-1617 in Participants With Advanced Cancer IM-1617 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Immunome, Inc. | 175 | 2026-05-21 | 2026-09-29 |
| A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors 3H-10000 - Lung Cancer, Stomach Cancer | Phase 1 / Phase 2 | Recruiting | 3H Pharmaceuticals Co., Ltd. | 170 | 2026-01-04 | 2026-01-21 |
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine - Stomach Cancer, Stomach Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-09-10 | 2024-11-12 |
| Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors Intraperitoneal infusion of FAST CEA-targeted CAR-T - Colorectal Cancer, Stomach Cancer | Phase 1 | Recruiting | Weijia Fang, MD | 18 | 2024-07-24 | 2026-01-23 |
| CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer CA-4948, Nivolumab, Pembrolizumab - Gastric Cancer, Esophageal Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 42 | 2023-06-02 | 2026-04-27 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors CEA CAR-T cells - Colorectal Cancer, Esophageal Cancer | Phase 1 | Completed | Chongqing Precision Biotech Co., Ltd | 30 | 2021-09-10 | 2026-07-09 |
| Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) PIPAC+SOX+OLAPARIB - Stomach Cancer, Gastric Cancer | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 30 | 2020-12-01 | 2020-06-01 |
| Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer Alpelisib, Paclitaxel - Solid Tumor, Stomach Cancer | Phase 1 / Phase 2 | Unknown | Seoul National University Bundang Hospital | 55 | 2020-09-01 | 2021-08-24 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| AZD8186 and Paclitaxel in Advanced Gastric Cancer AZD8186 in combination with paclitaxel - Solid Tumor, Stomach Cancer | Phase 1 / Phase 2 | Unknown | Seoul National University Bundang Hospital | 49 | 2019-05-14 | 2019-06-28 |
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 LYN00101 - Ovarian Cancer, Cervical Cancer | Phase 1 | Withdrawn | Lynkcell Inc. | 2019-04-03 | 2020-03-11 | |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies INCAGN02390 - Cervical Cancer, Gastric Cancer | Phase 1 | Completed | Incyte Corporation | 40 | 2018-09-24 | 2021-11-15 |
| A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy Simvastatin - Stomach Cancer | Phase 1 | Unknown | Samsung Medical Center | 9 | 2018-01-04 | 2019-12-30 |
| Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab - Gastric Cancer, Stomach Cancer | Phase 1 / Phase 2 | Completed | MacroGenics | 95 | 2016-01-01 | 2025-03-17 |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer KD019 - Esophageal Cancer, Stomach Cancer | Phase 1 | Withdrawn | NYU Langone Health | 2014-12-01 | 2014-08-01 | |
| Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors MGCD0103 & Docetaxel - Breast Cancer, Lung Cancer | Phase 1 | Terminated | Mirati Therapeutics Inc. | 54 | 2007-08-01 | 2015-01-08 |
| Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer Docetaxel, Capecitabine and Oxaliplatin - Stomach Cancer | Phase 1 | Completed | Asan Medical Center | 22 | 2006-03-01 | 2020-01-18 |
| Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers CHP-HER2, CHP-NY-ESO-1 - Esophageal Cancer, Lung Cancer | Phase 1 | Completed | Ludwig Institute for Cancer Research | 9 | 2005-07-01 | 2009-03-03 |
| Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer oxaliplatin, capecitabine, radiotherapy - Stomach Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Completed | Lund University Hospital | 106 | 2003-06-01 | 2011-10-17 |
Stomach Neoplasms (20) · Esophageal Neoplasms (10) · Colorectal Neoplasms (5) · Pancreatic Neoplasms (5) · Breast Neoplasms (4) · Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Adenocarcinoma (2) · Colonic Neoplasms (2) · Gallbladder Neoplasms (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Uterine Cervical Neoplasms (2)
Digestive System Diseases (20) · Digestive System Neoplasms (20) · Gastrointestinal Diseases (20) · Neoplasms by Site (20) · Stomach Diseases (20) · Gastrointestinal Neoplasms (19) · Neoplasms (18) · Esophageal Diseases (10) · Head and Neck Neoplasms (9) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Colonic Diseases (7) · Intestinal Diseases (7) · Intestinal Neoplasms (7) · Lung Diseases (6)
pembrolizumab (3) · Capecitabine (2) · Cyclophosphamide (2) · Docetaxel (2) · Interleukin-2 (2) · Oxaliplatin (2) · Paclitaxel (2) · fludarabine (2) · AZD8186 (1) · Alpelisib (1) · CA-4948 (1) · Drug Therapy (1) · Nivolumab (1) · Radiotherapy (1) · Simvastatin (1)
Seoul National University Bundang Hospital (2) · 3H Pharmaceuticals Co., Ltd. (1) · Asan Medical Center (1) · Brian Henick, MD (1) · Chongqing Precision Biotech Co., Ltd (1) · Essen Biotech (1) · Immunome, Inc. (1) · Incyte Corporation (1) · Intima Bioscience, Inc. (1) · Ludwig Institute for Cancer Research (1) · Lund University Hospital (1) · Lynkcell Inc. (1) · MacroGenics (1) · Mirati Therapeutics Inc. (1) · NYU Langone Health (1)
United States (8) · China (5) · South Korea (5) · Canada (1) · Japan (1) · Singapore (1) · Sweden (1) · Taiwan (1)
Anders Johnsson, MD, PhD (1) · Birendra K Sah, PH D (1) · Brian Henick, MD (1) · Chen Li, PH D (1) · Emil Lou, MD, PhD (1) · Gregory Reid, MSc, MBA (1) · Hiroshi Shiku, M.D. (1) · Jennifer Wu, MD (1) · Jingwang Bi, M.D (1) · Keun-Wook Lee, MD, PhD (1) · Keun-Wook Lee, MD. & Ph.D (1) · Nawel Bourayou, MD (1) · Patrick Grierson, M.D., Ph.D. (1) · Yoon-Koo Kang, MD, PhD (1) · Zhenggang Zhu, PH D (1)
PMID 32653053, PMID 37036671, PMID 37104758, PMID 40315882, PMID 40673842